This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Bellicum Pharmaceuticals (BPXA) Stock Overview

BPXA fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Risk Analysis

Does not have a meaningful market cap (€772K)

Has less than 1 year of cash runway

Highly volatile share price over the past 3 months

Does not have meaningful revenue ($2M)

BPXA Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW440,300 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.

Grow your followingReal investors. The kind who actually invest, not scroll past.

Unlock free accessFree premium subscription for consistent and quality authors.

Learn more Create Narrative

440,300 investors already sharing narratives

View all narratives

Bellicum Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Bellicum Pharmaceuticals
Historical stock prices
Current Share Price	€0.064
52 Week High	€0.19
52 Week Low	€0.037
Beta	1.38
1 Month Change	0%
3 Month Change	-30.98%
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-44.78%

Recent updates

Shareholder Returns

	BPXA	DE Biotechs	DE Market
7D	0%	-0.8%	-1.8%
1Y	n/a	-4.9%	4.2%

Return vs Industry: Insufficient data to determine how BPXA performed against the German Biotechs industry.

Return vs Market: Insufficient data to determine how BPXA performed against the German Market.

Price Volatility

Is BPXA's price volatile compared to industry and market?
BPXA volatility
BPXA Average Weekly Movement	38.0%
Biotechs Industry Average Movement	5.5%
Market Average Movement	5.0%
10% most volatile stocks in DE Market	12.6%
10% least volatile stocks in DE Market	2.5%

Stable Share Price: BPXA's share price has been volatile over the past 3 months.

Volatility Over Time: Insufficient data to determine BPXA's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2004	13	Dave Maggio	www.bellicum.com

Bellicum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company’s clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen. Its clinical product candidates also include BPX-603, an autologous dual-switch GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing human epidermal growth factor receptor 2 antigen.

Bellicum Pharmaceuticals, Inc. Fundamentals Summary

How do Bellicum Pharmaceuticals's earnings and revenue compare to its market cap?
BPXA fundamental statistics
Market cap	€772.38k
Earnings (TTM)	-€21.01m
Revenue (TTM)	€1.42m

0.5x

P/S Ratio

0.0x

P/E Ratio

Is BPXA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BPXA income statement (TTM)
Revenue	US$1.51m
Cost of Revenue	US$18.63m
Gross Profit	-US$17.12m
Other Expenses	US$5.26m
Earnings	-US$22.38m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-1.84
Gross Margin	-1,135.08%
Net Profit Margin	-1,483.95%
Debt/Equity Ratio	0%

How did BPXA perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/04/20 18:31
End of Day Share Price	2024/03/04 00:00
Earnings	2023/09/30
Annual Earnings	2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Bellicum Pharmaceuticals, Inc. is covered by 8 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Elemer Piros	Cantor Fitzgerald & Co.
Charles Butler	Guggenheim Securities, LLC
Biren Amin	Jefferies LLC

Bellicum Pharmaceuticals, Inc.BST:BPXA Stock Report